These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 27643650)

  • 1. Phase I Clinical Study of Irinotecan Plus S-1 in Patients With Advanced or Recurrent Cervical Cancer Previously Treated With Platinum-Based Chemotherapy.
    Mabuchi S; Yokoi E; Owa T; Kozasa K; Yamashita M; Kobayashi E; Tomimatsu T; Yoki T; Tsutui T; Kimura T
    Int J Gynecol Cancer; 2016 Sep; 26(7):1281-7. PubMed ID: 27643650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of irinotecan combined with S-1 in patients with advanced or recurrent cervical cancer previously treated with platinum based chemotherapy.
    Mabuchi S; Yokoi E; Shimura K; Komura N; Matsumoto Y; Sawada K; Isobe A; Tsutsui T; Kitada F; Kimura T
    Int J Gynecol Cancer; 2019 Mar; 29(3):474-479. PubMed ID: 30833436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer.
    Han B; Jung JY; Kim HS; Cho JW; Kim KC; Lim H; Kang HS; Ha HI; Kim MJ; Kim JH; Choi DR; Jang G; Kim JH; Song H; Zang DY
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):949-958. PubMed ID: 27628195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
    Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer.
    Choi YH; Kim TW; Lee SS; Hong YS; Ryu MH; Lee JL; Chang HM; Kang YK
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):905-12. PubMed ID: 21290246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
    Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer.
    Tsuda H; Hashiguchi Y; Nishimura S; Miyama M; Nakata S; Kawamura N; Negoro S
    Br J Cancer; 2004 Sep; 91(6):1032-7. PubMed ID: 15292935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer.
    Yamada Y; Yasui H; Goto A; Arai T; Ura T; Hamaguchi T; Muro K; Shimada Y; Shirao K
    Int J Clin Oncol; 2003 Dec; 8(6):374-80. PubMed ID: 14663640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.
    Briasoulis E; Golfinopoulos V; Karina M; Papakostas P; Pavlidis N; Fountzilas G
    Anticancer Drugs; 2010 Sep; 21(8):785-9. PubMed ID: 20647930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).
    Tanabe K; Fujii M; Nishikawa K; Kunisaki C; Tsuji A; Matsuhashi N; Takagane A; Ohno T; Kawase T; Kochi M; Yoshida K; Kakeji Y; Ichikawa W; Chin K; Terashima M; Takeuchi M; Nakajima T
    Ann Oncol; 2015 Sep; 26(9):1916-1922. PubMed ID: 26109630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.
    Oh SY; Ju YT; Choi SK; Ha CY; Lee WS; Kim HG; Lee GW; Kwon HC; Kang JH
    Invest New Drugs; 2011 Oct; 29(5):1050-6. PubMed ID: 20238142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of postoperative radiotherapy concurrent with S-1 in patients with gastric cancer.
    Qiu M; Peng XC; Bi F; Wang X; Li Q; Xu F; Li ZP; Shen YL; Liu JY; Zhao YQ; Cao D; Gou HF; Yang Y; Chen Y; Yi C
    Med Oncol; 2015 Jul; 32(7):191. PubMed ID: 26025485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.
    Huang J; Xu B; Liu Y; Huang J; Lu P; Ba Y; Wu L; Bai Y; Zhang S; Feng J; Cheng Y; Li J; Wen L; Yuan X; Ma C; Hu C; Fan Q; Wang X
    Cancer Commun (Lond); 2019 Apr; 39(1):16. PubMed ID: 30940189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients.
    Yoda S; Soejima K; Yasuda H; Naoki K; Kawada I; Watanabe H; Nakachi I; Satomi R; Nakayama S; Ikemura S; Terai H; Sato T; Morosawa M; Asano K
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):717-22. PubMed ID: 21152917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
    Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosage escalation study of S-1 and irinotecan in metronomic chemotherapy against advanced colorectal cancer.
    Ogata Y; Sasatomi T; Akagi Y; Ishibashi N; Mori S; Shirouzu K
    Kurume Med J; 2009; 56(1-2):1-7. PubMed ID: 20103995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer.
    Hata T; Fukunaga M; Murata K; Uemura Y; Fukuzaki T; Ota H; Ohue M; Ohnishi T; Tanaka N; Takemasa I; Mizushima T; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1657-63. PubMed ID: 23543294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of concurrent weekly carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy as an adjuvant treatment for early-stage cervical cancer patients with positive pelvic lymph nodes.
    Mabuchi S; Takahashi R; Isohashi F; Yokoi T; Ito K; Tsutui T; Ogata T; Yoshioka Y; Ogawa K; Kimura T
    Int J Gynecol Cancer; 2013 Sep; 23(7):1279-86. PubMed ID: 23835505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma.
    Yanagimoto H; Satoi S; Sho M; Akahori T; Yamamoto T; Hirooka S; Yamaki S; Kotsuka M; Ryota H; Kinoshita S; Nishiwada S; Nagai M; Ikeda N; Tsuta K; Nakajima Y; Kon M
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):35-41. PubMed ID: 26645403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer.
    Komatsu Y; Yuki S; Fuse N; Kato T; Miyagishima T; Kudo M; Kunieda Y; Tateyama M; Wakahama O; Meguro T; Sakata Y; Asaka M
    Adv Ther; 2010 Jul; 27(7):483-92. PubMed ID: 20559897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.